ProMab Biotechnologies Overview
- Year Founded
-
2001
- Status
-
Private
- Latest Deal Type
-
Debt - PPP
- Financing Rounds
-
3
- Investments
-
1
ProMab Biotechnologies General Information
Description
Developer of recombinant proteins, antibodies and engineered cell lines intended to improve human health with a focus on the field of immunotherapy. The company offers its products through the integration of bioinformatics, molecular biology, protein expression, purification techniques, gene cloning, microbiology and immunology, using novel technologies, thereby helping to deliver research and diagnostic products and for the global biomedical research community through collaborations, partnerships and joint ventures with other biotechnology and bio-reagent companies.
Contact Information
Website
www.promab.comCorporate Office
- 2600 Hilltop Drive
- Building B
- Richmond, CA 94806
- United States
Corporate Office
- 2600 Hilltop Drive
- Building B
- Richmond, CA 94806
- United States
ProMab Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ProMab Biotechnologies Comparisons
Industry
Financing
Details
ProMab Biotechnologies Competitors (47)
One of ProMab Biotechnologies’s 47 competitors is Abcam, a Corporate Backed or Acquired company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abcam | Corporate Backed or Acquired | Cambridge, United Kingdom | ||||
| ProSci (Biotechnology) | Private Equity-Backed | Poway, CA | ||||
| Novus Biologicals | Formerly PE-Backed | Centennial, CO | ||||
| BioLegend | Formerly Accelerator/Incubator backed | San Diego, CA | ||||
| GeneTex | Formerly VC-backed | Irvine, CA |
ProMab Biotechnologies Patents
ProMab Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025221669-A1 | Fusion protein comprising il-12 and gm-csf | Pending | 18-Apr-2024 | ||
| WO-2025188726-A1 | Il-12 activates nk cells transfected with car rna-lnp | Pending | 08-Mar-2024 | ||
| WO-2025188726-A8 | Il-12 activates nk cells transfected with car rna-lnp | Pending | 08-Mar-2024 | ||
| WO-2025155485-A1 | Ror-1 antibody and ror-1-car-t cells | Pending | 19-Jan-2024 | ||
| WO-2025024674-A2 | Method for treating local and distant tumors | Inactive | 26-Jul-2023 | C12N15/88 |
ProMab Biotechnologies Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ProMab Biotechnologies Acquisitions (1)
ProMab Biotechnologies’s most recent deal was a Merger/Acquisition with One World Lab. The deal was made on 05-Dec-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| One World Lab | 05-Dec-2017 | Merger/Acquisition | Distributors (Healthcare) |
ProMab Biotechnologies FAQs
-
When was ProMab Biotechnologies founded?
ProMab Biotechnologies was founded in 2001.
-
Where is ProMab Biotechnologies headquartered?
ProMab Biotechnologies is headquartered in Richmond, CA.
-
What industry is ProMab Biotechnologies in?
ProMab Biotechnologies’s primary industry is Biotechnology.
-
Is ProMab Biotechnologies a private or public company?
ProMab Biotechnologies is a Private company.
-
What is ProMab Biotechnologies’s current revenue?
The current revenue for ProMab Biotechnologies is .
-
Who are ProMab Biotechnologies’s investors?
Shanghai Shineton Investment has invested in ProMab Biotechnologies.
-
Who are ProMab Biotechnologies’s competitors?
Abcam, ProSci (Biotechnology), Novus Biologicals, BioLegend, and GeneTex are some of the 47 competitors of ProMab Biotechnologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process